Search
Immuneering Corp
IMRXAdd to Watchlist
4.340USD
-0.040-0.91%
Close 09-24 16:00（ET）
280.80MMarket Cap
LossP/E TTM
After-hours 18:50 (ET)4.300USD-0.045-1.04%
After-hours 18:50 (ET)Immuneering Corp (IMRX) Stock Price Target & Forecast
Analyst Rating
Based on 7 analysts giving stock ratings to Immuneering Corp in the past month.
Buy
2 Strong Buy
5 Buy
0 Hold
0 Sell
0 Strong Sell
Target Price
17.167USD+291.93%
IMRX Analyst Recommendation Trends
In the current month, IMRX has received 5 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. IMRX average Analyst price target in the last month is 17.167.
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
2026-02
2
2
2
2
2
2
2
2
5
5
4
4
4
4
4
4
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
7
7
6
6
6
6
6
6
IMRX Analyst Rating for Peer Comparison
Updated: Sep 24, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Beigene Ltd
ONC
8
19
0
1
0
28
Ionis Pharmaceuticals Inc
IONS
6
14
6
0
0
26
argenx SE
ARGX
10
13
3
0
0
26
Insmed Inc
INSM
7
17
0
0
0
24
CRISPR Therapeutics AG
CRSP
4
9
11
0
0
24
IQVIA Holdings Inc
IQV
8
12
4
0
0
24
Kymera Therapeutics Inc
KYMR
9
12
2
0
0
23
Revolution Medicines Inc
RVMD
8
13
1
0
0
22
Cytokinetics Inc
CYTK
4
16
2
0
0
22
Tempus AI Inc
TEM
5
6
7
1
1
20
Financial Forecasting
Based on analysts' estimates, IMRX EPS is projected to reach -0.306 in FY2026Q3, following reported EPS of -0.267 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-0.31
-0.25
-0.27
-0.31
-0.34
Actual
-0.18
-0.21
-0.27
--
--
Surprise
+42.98%
+17.39%
+0.40%
--
--
FAQs
What is Immuneering Corp's price target?
Analysts forecast that Immuneering Corp's price target is USD 17.17, with the highest forecast at USD 30.00 and the lowest forecast at USD 12.00.
How have Immuneering CorpIMRX's recent earnings per share performed?
The market expectation was USD -0.27, while Immuneering CorpIMRX's earnings per share (EPS) for the previous quarter was USD -0.21. EPS for the next quarter is expected at USD -0.31.
What is the analyst rating for Immuneering Corp?
Based on the ratings of Immuneering Corp's stock from 7 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.